/
We are one of the world s leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Our mission is to accelerate the global development of safe and effective medical therapeutics.
Margins and capital returns are both well above average: 21.14% operating margin, ROIC at 56.48%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 20.0%, still solid.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$2.68B
▲ +20.0% YoY
Net Income (TTM)
$460M
▲ +11.6% YoY
Op. Margin
21.02%
ROIC
86.00%
▲ +12.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$711M
▲ +19.2% YoY
Op. Cash Flow (TTM)
$739M
▲ +17.1% YoY
Net Debt
-$507M
Net Cash Position
Cash & Equiv.
$653M
5Y CAGR: +22.3%
5Y CAGR: +24.6%
Continue Research